Keryx Pharma: Citigroup Says EU Approval Was As Expected And Doesn't Change The Banks' Sell Thesis, Maintains PT $1.50

by Paul Quintaro, Benzinga Editor

September 24, 2015 12:27 PM | 4 seconds read | Make a Comment

Partnership is the likely path to the Eurozone market according to Citi

Posted In: News Reiteration Analyst Ratings

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.